A newly developed immunosuppressant, FTY720, has a unique mechanism that is quite different from those of conventional immunosuppressants, and is presumed to be mediated through decreases in the number of peripheral lymphocytes, especially helper T cells. This study was performed to ascertain whether this innovative drug could prolong islet allograft survival. The donors were inbred Lewis rats and the recipients were ACI rats ren dered hyperglycemic with intravenous streptozotocin. In the study group, FTY720 dissolved in distilled water was orally administered at a dose of 5 mg/kg to the recipient ACI rats 1 day before and on the day of grafting. In the control group, only distilled water was orally administered to the recipient ACI rats on the day before and the day of grafting. Two thousand islets were transplanted into the portal vein of the recipient rats in the study and control groups immediately after isolation. The graft survival time in the study group was significantly longer than that in the control group, indicating that FTY720 retains a potent effect on the prolongation of islet allograft survival. FTY720 could become a useful immunosuppressant for future clinical islet allotransplantation.
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INTRODUCTION

MATERIALS AND METHODS
Animals
The donors were inbred male Lewis rats, 8-10 weeks of age, and the recipients were inbred male ACI rats, 
Administration of Immunosuppressant
In the study group, FTY720 dissolved in distilled water (0.4 mL) at a dose of 5 mg/kg was orally administered to each recipient ACI rat on the day before and the day of grafting. In the control group of ACI rats, only distilled water (0.4 mL) was orally administered to each recipient, on the same 2 days.
Islet Transplantation
Approximately 2000 islets were transplanted into the portal vein via the superior mesenteric vein of each recipient rat in the study and control groups immediately after isolation. Cessation of graft function was defined as the first of 2 consecutive days of recurrent hyperglyce mia (nonfasting blood glucose >200 mg/dL). Body weights and urinary glucose levels were measured twice a week after transplantation.
Statistics
The glucose levels were expressed as means ± SE.
Student's f-test was employed for statistical analysis. A p-value of less than 0.05 was considered to be statisti cally significant. The graft survival of the study group with FTY720 was significantly longer than that of the control group (p < 0.05).
RESULTS
In
DISCUSSION
Islet transplantation offers numerous advantages. It is
much safer and is more easily repeated than pancreatic organ transplantation. Also, it may, in the future, be used for xenotransplants, especially for free grafts (porcine islets, etc.) (7) . However, the 1-year survival rate of clinical islet allografts (27%) (12) is still much lower than that of pancreatic organ allografts (75%) (18). This is thought to be attributable to the following factors: nonfunctioning of isolated islets (2,23) , the small number of transplanted islets (6,7) , the immunogenicity of iso lated islets (6,7) , transplantation to inappropriate sites 
